Thursday, September 5, 2013

ThromboGenics acquires rights to eye treatment technology

BRUSSELS (Reuters) - Belgian biopharmaceutical company ThromboGenics said on Thursday it had entered into an agreement with British peer Bicycle Therapeutics to develop and launch new drugs to treat opthalmic diseases.

No comments:

Post a Comment

Subscribe Now: Feed Icon